Provided by Tiger Fintech (Singapore) Pte. Ltd.

3SBIO

11.960
-0.100-0.83%
Volume:28.58M
Turnover:341.06M
Market Cap:28.68B
PE:13.03
High:12.140
Open:12.020
Low:11.700
Close:12.060
Loading ...

3SBio's Lung Cancer Drug Gets Breakthrough Therapy Designation in China

MT Newswires Live
·
18 Apr

BRIEF-3Sbio Says 707 Injection (Anti-Vegf/Pd-1 Bispecific Antibody) Granted Breakthrough Therapy Designation By NMPA

Reuters
·
17 Apr

3SBio - 707 Injection (Anti-Vegf/Pd-1 Bispecific Antibody) Granted Breakthrough Therapy Designation by Nmpa

THOMSON REUTERS
·
17 Apr

3SBio's 2024 Profit Jumps 35%

MT Newswires Live
·
26 Mar

Stock Track | 3SBIO Soars 5.19% Pre-Market on Strong Financial Results and Dividend Announcement

Stock Track
·
26 Mar

Stock Track | 3SBIO Soars 5.19% Following Strong Financial Results and Dividend Announcement

Stock Track
·
26 Mar

BRIEF-3SBIO Announces Final Dividend Of HKD25 Cents Per Share

Reuters
·
25 Mar

3SBio FY Adjusted Ebitda RMB 3,402.3 Million

THOMSON REUTERS
·
25 Mar

3SBio FY Basic EPS RMB 0.86

THOMSON REUTERS
·
25 Mar

3SBio FY Gross Margin 86%

THOMSON REUTERS
·
25 Mar

3SBio Inc. (HKG:1530) Soars 27% But It's A Story Of Risk Vs Reward

Simply Wall St.
·
11 Mar

3SBio Inc.'s (HKG:1530) Stock Is Going Strong: Have Financials A Role To Play?

Simply Wall St.
·
13 Feb

BRIEF-3SBio Announces Cooperation With Duality Biologics In Respect Of Her2 Adc Drug

Reuters
·
13 Jan

3SBio Unit Gets Commercialization Rights for Duality Biologics' Cancer Drug in China, Hong Kong, Macau

MT Newswires Live
·
13 Jan

3SBio - Cooperation Between 3SBio Inc. and Duality Biologics in Respect of Her2 ADC Drug

THOMSON REUTERS
·
13 Jan

3SBio Cancels All Treasury Shares

MT Newswires Live
·
18 Dec 2024

3SBio's Unit Gets Exclusive Commercialization Rights for Clifutinib Besylate in Mainland China

MT Newswires Live
·
26 Nov 2024

BRIEF-3SBio Announces Cooperation Between Shenyang Sunshine And Sunshine Lake Pharma

Reuters
·
25 Nov 2024

3SBio - Cooperation Between Shenyang Sunshine and Sunshine Lake Pharma in Respect of Clifutinib Besylate

THOMSON REUTERS
·
25 Nov 2024

The five-year underlying earnings growth at 3SBio (HKG:1530) is promising, but the shareholders are still in the red over that time

Simply Wall St.
·
25 Nov 2024